We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cytocom Inc | NASDAQ:CBLI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.17 | 3.18 | 3.41 | 0 | 01:00:00 |
|
|
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
DELAWARE
|
20-0077155
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
|
73 High Street, Buffalo, New York
|
14203
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Large accelerated filer
|
¨
|
Accelerated filer
|
¨
|
Non-accelerated filer
|
¨
|
Smaller reporting company
|
x
|
Emerging Growth Company
|
¨
|
|
|
|
|
PAGE
|
|
|
||
ITEM 1.
|
|
|
|
||
|
||
|
||
|
||
|
||
|
||
ITEM 2.
|
||
ITEM 3.
|
||
ITEM 4.
|
||
|
|
|
|
||
ITEM 1.
|
||
ITEM 1A.
|
||
ITEM 2.
|
||
ITEM 3.
|
||
ITEM 4.
|
||
ITEM 5.
|
||
ITEM 6.
|
||
|
|
March 31, 2017
|
|
December 31, 2016
|
||||
|
(Unaudited)
|
|
|
||||
ASSETS
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
3,820,504
|
|
|
$
|
6,901,816
|
|
Short-term investments
|
9,253,471
|
|
|
8,343,657
|
|
||
Accounts receivable
|
516,432
|
|
|
352,700
|
|
||
Other current assets
|
231,026
|
|
|
289,768
|
|
||
Total current assets
|
13,821,433
|
|
|
15,887,941
|
|
||
Equipment, net
|
29,597
|
|
|
37,376
|
|
||
Other long-term assets
|
30,740
|
|
|
30,553
|
|
||
Total assets
|
$
|
13,881,770
|
|
|
$
|
15,955,870
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
379,213
|
|
|
$
|
336,435
|
|
Accrued expenses
|
1,185,329
|
|
|
1,823,235
|
|
||
Accrued warrant liability
|
1,071,117
|
|
|
949,419
|
|
||
Total current liabilities
|
2,635,659
|
|
|
3,109,089
|
|
||
Commitments and contingencies
|
—
|
|
|
—
|
|
||
Total liabilities
|
2,635,659
|
|
|
3,109,089
|
|
||
Stockholders’ equity:
|
|
|
|
||||
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2017 and December 31, 2016
|
—
|
|
|
—
|
|
||
Common stock, $.005 par value; 160,000,000 shares authorized, 10,987,166 shares issued and outstanding as of March 31, 2017 and December 31, 2016
|
54,932
|
|
|
54,932
|
|
||
Additional paid-in capital
|
158,773,753
|
|
|
158,773,753
|
|
||
Other comprehensive loss
|
(497,581
|
)
|
|
(564,559
|
)
|
||
Accumulated deficit
|
(152,403,850
|
)
|
|
(150,740,156
|
)
|
||
Total Cleveland BioLabs, Inc. stockholders’ equity
|
5,927,254
|
|
|
7,523,970
|
|
||
Noncontrolling interest in stockholders’ equity
|
5,318,857
|
|
|
5,322,811
|
|
||
Total stockholders’ equity
|
11,246,111
|
|
|
12,846,781
|
|
||
Total liabilities and stockholders’ equity
|
$
|
13,881,770
|
|
|
$
|
15,955,870
|
|
|
For the Three Months Ended
March 31, |
||||||
|
2017
|
|
2016
|
||||
Revenues:
|
|
|
|
||||
Grants and contracts
|
$
|
574,974
|
|
|
$
|
812,500
|
|
Operating expenses:
|
|
|
|
||||
Research and development
|
1,416,998
|
|
|
1,941,240
|
|
||
General and administrative
|
777,424
|
|
|
1,183,566
|
|
||
Total operating expenses
|
2,194,422
|
|
|
3,124,806
|
|
||
Loss from operations
|
(1,619,448
|
)
|
|
(2,312,306
|
)
|
||
Other income (expense):
|
|
|
|
||||
Interest and other income
|
49,289
|
|
|
181,765
|
|
||
Foreign exchange gain (loss)
|
(8,230
|
)
|
|
47,086
|
|
||
Change in value of warrant liability
|
(121,698
|
)
|
|
1,412,713
|
|
||
Total other income (expense)
|
(80,639
|
)
|
|
1,641,564
|
|
||
Net loss
|
(1,700,087
|
)
|
|
(670,742
|
)
|
||
Net loss attributable to noncontrolling interests
|
36,393
|
|
|
2,806
|
|
||
Net loss attributable to Cleveland BioLabs, Inc.
|
$
|
(1,663,694
|
)
|
|
$
|
(667,936
|
)
|
Net loss attributable to common stockholders per share of common stock, basic and diluted
|
$
|
(0.15
|
)
|
|
$
|
(0.06
|
)
|
Weighted average number of shares used in calculating net loss per share, basic and diluted
|
10,987,166
|
|
|
10,987,166
|
|
|
For the Three Months Ended
March 31, |
||||||
|
2017
|
|
2016
|
||||
Net loss including noncontrolling interests
|
$
|
(1,700,087
|
)
|
|
$
|
(670,742
|
)
|
Other comprehensive loss:
|
|
|
|
||||
Unrealized gain (loss) on short-term investments
|
(3,118
|
)
|
|
6,722
|
|
||
Foreign currency translation adjustment
|
102,535
|
|
|
23,321
|
|
||
Comprehensive loss including noncontrolling interests
|
(1,600,670
|
)
|
|
(640,699
|
)
|
||
Comprehensive loss (gain) attributable to noncontrolling interests
|
3,954
|
|
|
(27,082
|
)
|
||
Comprehensive loss attributable to Cleveland BioLabs, Inc.
|
$
|
(1,596,716
|
)
|
|
$
|
(667,781
|
)
|
|
Common Stock
|
|
Treasury Stock
|
|
Additional
Paid-In Capital |
||||||||||||
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
|||||||||
Balance at December 31, 2016
|
10,987,166
|
|
|
$
|
54,932
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
158,773,753
|
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Unrealized loss on short-term investments
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Foreign currency translation
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
Balance at March 31, 2017
|
10,987,166
|
|
|
$
|
54,932
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
158,773,753
|
|
|
Accumulated Other
Comprehensive Income (Loss) |
|
Accumulated
Deficit |
|
Noncontrolling
Interests |
|
Total
|
||||||||
Balance at December 31, 2016
|
$
|
(564,559
|
)
|
|
$
|
(150,740,156
|
)
|
|
$
|
5,322,811
|
|
|
$
|
12,846,781
|
|
Net loss
|
—
|
|
|
(1,663,694
|
)
|
|
(36,393
|
)
|
|
(1,700,087
|
)
|
||||
Unrealized loss on short-term investments
|
(3,118
|
)
|
|
—
|
|
|
—
|
|
|
(3,118
|
)
|
||||
Foreign currency translation
|
70,096
|
|
|
—
|
|
|
32,439
|
|
|
102,535
|
|
||||
Balance at March 31, 2017
|
$
|
(497,581
|
)
|
|
$
|
(152,403,850
|
)
|
|
$
|
5,318,857
|
|
|
$
|
11,246,111
|
|
|
For the Three Months Ended March 31,
|
||||||
|
2017
|
|
2016
|
||||
Cash flows from operating activities:
|
|
||||||
Net loss
|
$
|
(1,700,087
|
)
|
|
$
|
(670,742
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
||||
Depreciation and amortization
|
5,716
|
|
|
26,617
|
|
||
Non-cash investment income
|
(14,993
|
)
|
|
(9,410
|
)
|
||
Gain on equipment disposal
|
(6,727
|
)
|
|
—
|
|
||
Non-cash compensation
|
—
|
|
|
11,457
|
|
||
Change in value of warrant liability
|
121,698
|
|
|
(1,412,713
|
)
|
||
Changes in operating assets and liabilities:
|
|
|
|
||||
Accounts receivable and other current assets
|
(102,543
|
)
|
|
(554,013
|
)
|
||
Accounts payable and accrued expenses
|
(621,218
|
)
|
|
268,358
|
|
||
Deferred revenue
|
—
|
|
|
83,703
|
|
||
Net cash used in operating activities
|
(2,318,154
|
)
|
|
(2,256,743
|
)
|
||
Cash flows from investing activities:
|
|
|
|
||||
Purchase of short-term investments
|
(3,919,575
|
)
|
|
—
|
|
||
Sale of short-term investments
|
3,100,013
|
|
|
6,335,062
|
|
||
Proceeds from sale of equipment
|
8,938
|
|
|
15,327
|
|
||
Net cash provided by (used in) investing activities
|
(810,624
|
)
|
|
6,350,389
|
|
||
Cash flows from financing activities:
|
|
|
|
||||
Net proceeds from sale of treasury stock
|
—
|
|
|
539,998
|
|
||
Net cash provided by financing activities
|
—
|
|
|
539,998
|
|
||
Effect of exchange rate change on cash and equivalents
|
47,466
|
|
|
42,760
|
|
||
Increase (decrease) in cash and cash equivalents
|
(3,081,312
|
)
|
|
4,676,404
|
|
||
Cash and cash equivalents at beginning of period
|
6,901,816
|
|
|
5,918,424
|
|
||
Cash and cash equivalents at end of period
|
$
|
3,820,504
|
|
|
$
|
10,594,828
|
|
Supplemental disclosure of cash flow information:
|
|
|
|
||||
Cash paid during the period for interest
|
$
|
—
|
|
|
$
|
—
|
|
|
Three Months Ended
March 31, |
|
|
|||||
Customer
|
2017
|
|
2016
|
|
Variance
|
|||
Department of Defense
|
72.8
|
%
|
|
30.4
|
%
|
|
42.4
|
%
|
Russian Government Agencies
|
—
|
%
|
|
41.0
|
%
|
|
(41.0
|
)%
|
Incuron, LLC
|
27.2
|
%
|
|
28.6
|
%
|
|
(1.4
|
)%
|
Total
|
100.0
|
%
|
|
100.0
|
%
|
|
—
|
%
|
|
Unrealized loss on available-for-sale securities
|
|
Gains and losses on foreign exchange translations
|
|
Total
|
||||||
Beginning balance
|
$
|
(2,286
|
)
|
|
$
|
(562,273
|
)
|
|
$
|
(564,559
|
)
|
Other comprehensive income/(loss) before reclassifications
|
(3,118
|
)
|
|
102,535
|
|
|
99,417
|
|
|||
Amounts reclassified from accumulated other comprehensive loss
|
—
|
|
|
(32,439
|
)
|
|
(32,439
|
)
|
|||
Ending balance
|
$
|
(5,404
|
)
|
|
$
|
(492,177
|
)
|
|
$
|
(497,581
|
)
|
|
As of March 31,
|
||||
Common Equivalent Securities
|
2017
|
|
2016
|
||
Warrants
|
2,107,047
|
|
|
2,222,155
|
|
Options
|
226,921
|
|
|
336,942
|
|
Total
|
2,333,968
|
|
|
2,559,097
|
|
•
|
Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets;
|
•
|
Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and
|
•
|
Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.
|
|
As of March 31, 2017
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Cash and cash equivalents
|
$
|
808,075
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
808,075
|
|
Short-term investments
|
8,011,850
|
|
|
1,241,621
|
|
|
—
|
|
|
9,253,471
|
|
||||
Total assets
|
$
|
8,819,925
|
|
|
$
|
1,241,621
|
|
|
$
|
—
|
|
|
$
|
10,061,546
|
|
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Accrued warrant liability
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,071,117
|
|
|
$
|
1,071,117
|
|
|
As of December 31, 2016
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Assets:
|
|
|
|
|
|
|
|
||||||||
Cash and cash equivalents
|
$
|
2,436,589
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
2,436,589
|
|
Short-term investments
|
7,487,365
|
|
|
856,292
|
|
|
—
|
|
|
8,343,657
|
|
||||
Total assets
|
$
|
9,923,954
|
|
|
$
|
856,292
|
|
|
$
|
—
|
|
|
$
|
10,780,246
|
|
Liabilities:
|
|
|
|
|
|
|
|
||||||||
Accrued warrant liability
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
949,419
|
|
|
$
|
949,419
|
|
|
March 31, 2017
|
|
December 31, 2016
|
||||
Stock Price
|
$
|
1.60
|
|
|
$
|
1.42
|
|
Exercise Price
|
$3.00 - $60.00
|
|
|
$3.00 - $60.00
|
|
||
Term in years
|
0.57 – 4.35
|
|
|
0.17 - 4.60
|
|
||
Volatility
|
60.11% - 85.65%
|
|
|
52.88% - 96.36%
|
|
||
Annual rate of quarterly dividends
|
—
|
%
|
|
—
|
%
|
||
Discount rate- bond equivalent yield
|
.58% - 1.79%
|
|
|
.15% - 1.84%
|
|
|
Three Months Ended
March 31, 2017 |
|
Three Months Ended March 31, 2016
|
||||
|
Accrued
Warrant Liability |
|
Accrued
Warrant Liability |
||||
Beginning Balance
|
$
|
949,419
|
|
|
$
|
4,048,900
|
|
Total (gains) or losses, realized and unrealized, included in earnings (1)
|
121,698
|
|
|
(1,412,713
|
)
|
||
Issuances
|
—
|
|
|
—
|
|
||
Settlements
|
—
|
|
|
—
|
|
||
Ending Balance
|
$
|
1,071,117
|
|
|
$
|
2,636,187
|
|
(1)
|
Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were
no
realized gains or losses for the
three
months ended
March 31, 2017
and
2016
.
|
|
Total Stock
Options
Outstanding
|
|
Weighted
Average Exercise
Price per Share
|
|||
December 31, 2016
|
233,367
|
|
|
$
|
41.98
|
|
Granted
|
—
|
|
|
—
|
|
|
Vested
|
—
|
|
|
—
|
|
|
Forfeited, Canceled
|
(6,446
|
)
|
|
64.99
|
|
|
March 31, 2017
|
226,921
|
|
|
$
|
41.32
|
|
|
As of March 31, 2017
|
||||||
|
Stock Options
Outstanding
|
|
Vested Stock
Options
|
||||
Quantity
|
226,921
|
|
|
226,921
|
|
||
Weighted-average exercise price
|
$
|
41.32
|
|
|
$
|
41.32
|
|
Weighted Average Remaining Contractual Term (in Years)
|
5.83
|
|
|
5.83
|
|
||
Intrinsic value
|
$
|
—
|
|
|
$
|
—
|
|
|
Number of
Warrants |
|
Weighted Average
Exercise Price |
|||
December 31, 2016
|
2,148,741
|
|
|
$
|
11.04
|
|
Granted
|
—
|
|
|
—
|
|
|
Exercised
|
—
|
|
|
—
|
|
|
Forfeited, Canceled
|
(41,694
|
)
|
|
3.00
|
|
|
March 31, 2017
|
2,107,047
|
|
|
$
|
11.20
|
|
|
Number of
Warrants |
|
Weighted Average
Exercise Price |
|||
December 31, 2016
|
2,148,741
|
|
|
$
|
11.04
|
|
Granted
|
—
|
|
|
—
|
|
|
Exercised
|
(1,181,235
|
)
|
|
3.64
|
|
|
Forfeited, Canceled
|
(41,694
|
)
|
|
3.00
|
|
|
May 5, 2017
|
925,812
|
|
|
$
|
20.84
|
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
|
Program
|
|
Three Months Ended March 31,
|
|
|
||||||||
Funding Source
|
2017
|
|
2016
|
|
Variance
|
||||||||
DoD
|
JWMRP Contract (1)
|
|
$
|
415,094
|
|
|
$
|
219,101
|
|
|
$
|
195,993
|
|
DoD
|
PRMRP Contract (2)
|
|
1,763
|
|
|
27,781
|
|
|
(26,018
|
)
|
|||
DoD
|
DTRA Contract (3)
|
|
1,886
|
|
|
—
|
|
|
1,886
|
|
|||
MPT
|
CBLB612 pre-clinical (4)
|
|
—
|
|
|
262,551
|
|
|
(262,551
|
)
|
|||
MPT
|
Entolimod colorectal cancer (4)
|
|
—
|
|
|
5,912
|
|
|
(5,912
|
)
|
|||
Incuron
|
Service contract
|
|
156,231
|
|
|
232,479
|
|
|
(76,248
|
)
|
|||
|
|
|
574,974
|
|
|
747,824
|
|
|
(172,850
|
)
|
|||
MPT
|
Mobilan pre-clinical (4)
|
|
—
|
|
|
64,676
|
|
|
(64,676
|
)
|
|||
|
|
|
$
|
574,974
|
|
|
$
|
812,500
|
|
|
$
|
(237,526
|
)
|
(1)
|
The Congressionally Directed Medical Research Programs (CDMRP) Joint Warfighter Medical Research Program (JWMRP) contract was awarded on September 1, 2015.
|
(2)
|
The CDMRP Peer Reviewed Medical Research Program (PRMRP) grant was awarded effective as of September 30, 2015.
|
(3)
|
The Defense Threat Reduction Agency (DTRA) contract had additional revenue recognized upon acknowledgment of final annual indirect rates for the fiscal year ended December 31, 2013.
|
(4)
|
The grants received from Russian government entities are denominated in Russian Rubles (RUB). The revenue above was calculated using average exchange rates for the periods presented.
|
|
|
|
|
|
|
|
|
As of March 31, 2017
|
||||||||||||||
Funding Source
|
|
Program
|
|
Total Award
Value
|
|
Funded Award
Value
|
|
Cumulative
Revenue
|
|
Funded
Backlog
|
|
Unfunded Backlog
|
||||||||||
DoD
|
|
JWMRP Contract
|
|
$
|
9,226,455
|
|
|
$
|
9,226,455
|
|
|
$
|
1,806,557
|
|
|
$
|
7,419,898
|
|
|
$
|
—
|
|
DoD
|
|
PRMRP Contract
|
|
6,573,992
|
|
|
6,573,992
|
|
|
71,014
|
|
|
6,502,978
|
|
|
—
|
|
|||||
|
|
|
|
$
|
15,800,447
|
|
|
$
|
15,800,447
|
|
|
$
|
1,877,571
|
|
|
$
|
13,922,876
|
|
|
$
|
—
|
|
|
Three Months Ended March 31,
|
|
|
||||||||
|
2017
|
|
2016
|
|
Variance
|
||||||
Entolimod for Biodefense Applications
|
$
|
1,202,837
|
|
|
$
|
871,511
|
|
|
$
|
331,326
|
|
CBLB612
|
21,732
|
|
|
377,976
|
|
|
(356,244
|
)
|
|||
Entolimod for Oncology Indications
|
70,680
|
|
|
512,996
|
|
|
(442,316
|
)
|
|||
|
1,295,249
|
|
|
1,762,483
|
|
|
(467,234
|
)
|
|||
Curaxins
|
53,632
|
|
|
117,579
|
|
|
(63,947
|
)
|
|||
Panacela product candidates
|
68,117
|
|
|
61,178
|
|
|
6,939
|
|
|||
Total research & development expenses
|
$
|
1,416,998
|
|
|
$
|
1,941,240
|
|
|
$
|
(524,242
|
)
|
•
|
From inception through
March 31, 2017
, we have raised $144.7 million of net equity capital, including amounts received from the exercise of options and warrants. We have also received $7.3 million in net proceeds from the issuance of long-term debt instruments;
|
•
|
DoD and BARDA have funded grants and contracts totaling $60.4 million for the development of entolimod for its biodefense indication;
|
•
|
The Russian Federation has funded a series of our contracts totaling $17.3 million, based on the exchange rates in effect on the date of funding. These contracts include a requirement for us to contribute matching funds, which we have satisfied or expect to satisfy with both the value of developed intellectual property at the time of award, incurred development expenses and future expenses;
|
•
|
We have been awarded $4.0 million in grants and contracts not described above, all of which have been recognized at
March 31, 2017
;
|
•
|
Incuron was formed to develop and commercialize the Curaxins product line, including its lead oncology drug candidate CBL0137. In 2015, we sold our ownership interest for approximately $4.0 million and retain a 2% royalty interest in the CBL0137 technology; and
|
•
|
Panacela was formed to develop and commercialize preclinical compounds, which were transferred to Panacela through assignment and lease agreements. RUSNANO contributed $9.0 million to Panacela and CBLI contributed $3.0 million plus intellectual property to Panacela. As of the date of this filing, CBLI owns 67.57% of Panacela.
|
|
For the Three Months Ended
March 31, |
||||||||||
|
2017
|
|
2016
|
|
Variance
|
||||||
Cash flows used in operating activities
|
$
|
(2,318,154
|
)
|
|
$
|
(2,256,743
|
)
|
|
$
|
(61,411
|
)
|
Cash flows provided by (used in) investing activities
|
(810,624
|
)
|
|
6,350,389
|
|
|
(7,161,013
|
)
|
|||
Cash flows provided by financing activities
|
—
|
|
|
539,998
|
|
|
(539,998
|
)
|
|||
Effect of exchange rate change on cash and equivalents
|
47,466
|
|
|
42,760
|
|
|
4,706
|
|
|||
Increase in cash and cash equivalents
|
(3,081,312
|
)
|
|
4,676,404
|
|
|
(7,757,716
|
)
|
|||
Cash and cash equivalents at beginning of period
|
6,901,816
|
|
|
5,918,424
|
|
|
983,392
|
|
|||
Cash and cash equivalents at end of period
|
$
|
3,820,504
|
|
|
$
|
10,594,828
|
|
|
$
|
(6,774,324
|
)
|
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
Item 4.
|
Controls and Procedures
|
Item 1.
|
Legal Proceedings
|
Item 1A.
|
Risk Factors
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
Item 3.
|
Defaults Upon Senior Securities
|
Item 4.
|
Mine Safety Disclosures
|
Item 5.
|
Other Information
|
Item 6.
|
Exhibits
|
(a)
|
The following exhibits are included as part of this report:
|
|
CLEVELAND BIOLABS, INC.
|
|
|
|
|
Dated: May 15, 2017
|
By:
|
/s/ YAKOV KOGAN
|
|
|
Yakov Kogan
|
|
|
Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
|
Dated: May 15, 2017
|
By:
|
/s/ John E. Szydlo
|
|
|
John E. Szydlo
|
|
|
Principal Financial Officer
|
|
|
(Principal Financial Officer)
|
1 Year Cytocom Chart |
1 Month Cytocom Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions